CPRX: Catalyst Pharmaceuticals, Inc. - Summary | Jitta

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Price
$12.13
Loss Chance
43.5%
6.75JITTA SCORE
36.98%Over Jitta Line
Jitta Ranking
57 / 1,156
826 / 5,063
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (74)
Recent Business Performance (100)
Financial Strength (82)
Return to Shareholders (44)
Competitive Advantage (76)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Cash Conversion CycleLess than 60 days
Key Stats
Jitta Score
Jitta Line
6.75
36.98%
1.29
147.43%
2.00
168.87%
Biotechnology
5.58
213.65%
6.29
22.35%
5.10
48.71%
COMPANY DESCRIPTION
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.